Bimatoprost: An effective second-line option in the treatment open-angle glaucoma and ocular hypertension

Bimatoprost (Lumigan®) is a synthetic prostamide analogue that lowers intraocular pressure (IOP) by increasing the outflow of aqueous humour. In patients with open-angle glaucoma or ocular hypertension, bimatoprost lowered IOP by more than 30% and was more effective than timolol and at least as effective as latanoprost. The long duration of action of bimatoprost allows for once-daily administration and effectively controls IOP throughout the dosage interval. Diurnal control of IOP with bimatoprost was better than with comparator agents in clinical trials. Bimatoprost is well tolerated; mild conjunctival hyperaemia was the most common drug-related event. Because systemic adverse effects have not been associated with bimatoprost use, it provides an effective option for patients intolerant of β-blockers or in whom this class of drug is contraindicated. Bimatoprost may also offer an effective treatment option for patients refractory to or intolerant of other IOP-lowering agents.